These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21122374)

  • 1. [Molecular subtypes and individualized treatment of breast cancer].
    Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
    [No Abstract]   [Full Text] [Related]  

  • 2. [Practice and consideration on neoadjuvant therapy for early breast cancer].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
    Petit T; Claude L; Carrie C
    Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 9. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P; Xu BH; Ma F; Li Q
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
    Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
    Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
    Jiang ZF; Shao ZM; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
    [No Abstract]   [Full Text] [Related]  

  • 16. Near-final word on adjuvant chemotherapy for breast cancer is good news.
    Vastag B
    J Natl Cancer Inst; 2005 Aug; 97(16):1178-9. PubMed ID: 16106020
    [No Abstract]   [Full Text] [Related]  

  • 17. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
    Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
    Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast cancer 1984: state of the art.
    Sledge GW
    Indiana Med; 1984 Dec; 77(12):935-9. PubMed ID: 6394645
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.